Clinical benefits with oseltamivir in treating influenza in adult populations: Results of a pooled and subgroup analysis

Clinical Drug Investigation

Volumn 23, Issue 9, 2003, Pages 561-569

  Singh, S ^a   Barghoorn, J ^e   Bagdonas, A ^b   Adler, J ^e   Treanor, J ^c   Kinnersley, N ^d   Ward, P ^d  

^a SARC Research Center   (United States)

^b Red Cross Hospital   (Lithuania)

^c UNIVERSITY OF ROCHESTER   (United States)

^d ROCHE PRODUCTS LTD   (United Kingdom)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PARACETAMOL; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; EPIDEMIC; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEALTH PROGRAM; HEALTH STATUS; HEART DISEASE; HIGH RISK POPULATION; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LABORATORY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIDE EFFECT; SLEEP; SYMPTOM; TREATMENT OUTCOME; VOMITING;

EID: 0141501525     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323090-00002     Document Type: Article

References (18)

1. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000; 49 (RR-03): 1-38
2. Cox NJ, Subbarao K. Global epidemiology of influenza: past and present. Ann Rev Med 2000; 51: 407-21
3. Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza III. New York: Elsevier Science BV, 1996: 17-25
4. Kavet J. A perspective on the significance of pandemic influenza. Am J Public Health 1977; 67: 1063-70
5. Monto AS. Influenza: quantifying morbidity and mortality. Am J Med 1987; 82: 20-5
6. Air GM, Laver WG. The neuraminidase of influenza virus. Proteins 1989; 6: 341-56
7. Jackson HC, Roberts NA, Wang ZM, et al. Management of influenza: use of new antivirals and resistance in perspective. Clin Drug Invest 2000; 20: 447-54
8. Kurowski M, Barrett J, Waalberg E, et al. Oral oseltamivir rapidly delivers active drug levels to middle ear and sinuses in humans [abstract no 509]. International Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20; Toronto
9. Nicholson KG, Aoki FY, Osterhaus ADME, et al. on behalf of the Neuraminidase Inhibitor Flu Treatment Investigator Group. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000; 355: 1845-50
10. Robson R, Jennings L, Saiedabadi N, et al. Oral oseltamivir reduces the duration of influenza illness by 2.7 days in previously healthy adults [abstract no. 80.019]. Proceedings of the 9th International Congress of Infectious Diseases; 2000 Apr 10-13; Buenos Aires, 184
11. Treanor JJ, Hayden FG, Vrooman PS, et al. for the US Oral Neuraminidase Study Group. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized, controlled trial. JAMA 2000; 283: 1016-24
12. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons Ltd, 1972
13. Martin C, Mahoney P, Ward P. Oral oseltamivir reduces febrile illness in patients considered at high risk of influenza complications. World Congress on options for the control of Influenza IV, Crete, Greece. International Congress Series 1219 (2001): 807-11.
14. Zaug M, Mahoney P, Ward P. Effective treatment of influenza with oral oseltamivir in a vaccinated population of high-risk patients. World Congress on options for the control of Influenza IV, Crete, Greece. International Congress Series 1219 (2001): 813-6.
15. Roche: Data on file
16. Hayden FG, Fritz R, Lobo MC, et al. Local and systemic cytokine responses during experimental human influenza A virus infection: relation to symptom formation and host defence. J Clin Invest 1998; 101: 643-9
17. Hayden FG, Treanor JT, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized, controlled trials for prevention and treatment. JAMA 1999; 282: 1240-6
18. Aoki F, MacLeod M, Paggiaro P, et al. Early administration of oral oseltamivir maximises the benefits of influenza treatment. J Antimicrob Chemother 2003; 51: 123-9